Comparative Pharmacology
Head-to-head clinical analysis: POLYSPORIN versus THERMAZENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYSPORIN versus THERMAZENE.
POLYSPORIN vs THERMAZENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and causing cell death. It also has anti-inflammatory effects by modulating cytokine release.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
1% cream applied topically once or twice daily; for burns, apply 1/16-inch thick layer over entire burn area.
None Documented
None Documented
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Terminal elimination half-life is approximately 22 hours (range 17–28 h) in patients with normal renal function, enabling twice-daily dosing in most cases.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Renal: ~65% unchanged; biliary/fecal: ~35% as metabolites and unchanged drug.
Category C
Category C
Topical Antibiotic
Topical Antibiotic